Idioma:

Zoledronate synergises with imatinib mesylate to inhibit Ph+ primary leukaemic cell growth

Segawa, Hidekazu ; Kimura, Shinya ; Kuroda, Junya ; Sato, Kiyoshi ; Yokota, Asumi ; Kawata, Eri ; Kamitsuji, Yuri ; Ashihara, Eishi ; Yuasa, Takeshi ; Fujiyama, Yoshihide ; Ottmann, Oliver G. ; Maekawa, Taira

British journal of haematology, 2005-08, Vol.130 (4), p.558-560 [Periódico revisado por pares]

Oxford, UK: Blackwell Science Ltd

Texto completo disponível

Citações Citado por

Enviar para

Título:
Zoledronate synergises with imatinib mesylate to inhibit Ph+ primary leukaemic cell growth
Autor: Segawa, Hidekazu ; Kimura, Shinya ; Kuroda, Junya ; Sato, Kiyoshi ; Yokota, Asumi ; Kawata, Eri ; Kamitsuji, Yuri ; Ashihara, Eishi ; Yuasa, Takeshi ; Fujiyama, Yoshihide ; Ottmann, Oliver G. ; Maekawa, Taira
Assuntos: Animals ; Antineoplastic Combined Chemotherapy Protocols ; Benzamides ; Biological and medical sciences ; bisphosphonate ; Diphosphonates ; Drug Synergism ; Hematologic and hematopoietic diseases ; Humans ; Imatinib Mesylate ; Imidazoles ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Medical sciences ; Mice ; Mice, SCID ; Models, Animal ; Neoplasm Transplantation ; Piperazines ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy ; prenylation ; primary leukaemic cells ; Pyrimidines ; Tumor Cells, Cultured ; zoledronate
É parte de: British journal of haematology, 2005-08, Vol.130 (4), p.558-560
Descrição: Summary We examined the in vivo effects and safety of the third generation bisphosphonate, zoledronate (ZOL) alone and combined with imatinib mesylate against primary Philadelphia chromosome positive (Ph+) leukaemic cells. ZOL inhibited the prenylation of Rap1A in leukaemic cells in vitro and synergised with imatinib to enhance the survival of mice engrafted with cells from imatinib‐responders, but not from non‐responders because of mutated BCR‐ABL. These findings suggest that the combination of ZOL and imatinib accelerate the eradication of Ph+ clone, resulting in better prognosis of Ph+ leukaemia patients who have not yet acquired mutations.
Editor: Oxford, UK: Blackwell Science Ltd
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Zoledronate synergises with imatinib mesylate to inhibit Ph+ primary leukaemic cell growth

Segawa, Hidekazu ; Kimura, Shinya ; Kuroda, Junya ; Sato, Kiyoshi ; Yokota, Asumi ; Kawata, Eri ; Kamitsuji, Yuri ; Ashihara, Eishi ; Yuasa, Takeshi ; Fujiyama, Yoshihide ; Ottmann, Oliver G. ; Maekawa, Taira

Oxford, UK: Blackwell Science Ltd

Buscando em bases de dados remotas. Favor aguardar.